标题
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
作者
关键词
-
出版物
Cancers
Volume 10, Issue 3, Pages 72
出版商
MDPI AG
发表日期
2018-03-15
DOI
10.3390/cancers10030072
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
- (2018) Aliya Noor Husain et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society
- (2018) Erik Thunnissen et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
- (2017) Paul Hofman EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
- (2017) Sun Min Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
- (2017) Trish Thorne-Nuzzo et al. Journal of Thoracic Oncology
- Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
- (2017) Antonio Marchetti et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma
- (2017) Vishwa Jeet Amatya et al. MODERN PATHOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers
- (2017) Yih-Leong Chang et al. Oncotarget
- Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor
- (2017) Kentaro Inamura et al. Cancer Medicine
- PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
- (2017) Sylvain Simon et al. OncoImmunology
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
- (2017) Paul Hofman Cancers
- Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer
- (2017) Kentaro Inamura Cancers
- EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
- (2017) et al. Cancers
- Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
- (2017) Kentaro Inamura Frontiers in Oncology
- BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas
- (2016) Harry C. Hwang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Impact of Recent Developments in Lung Cancer on the Practice of Pathology
- (2016) Philip T. Cagle et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
- (2016) David Planchard et al. Clinical Lung Cancer
- Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
- (2016) Giulio Rossi et al. CURRENT DRUG TARGETS
- Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
- (2016) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
- (2016) Eric Polley et al. JNCI-Journal of the National Cancer Institute
- The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs
- (2016) Patrick Micke et al. Journal of Thoracic Oncology
- KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung
- (2016) David H. Hwang et al. Journal of Thoracic Oncology
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
- (2016) Antonio Marchetti et al. Journal of Thoracic Oncology
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Testing for ROS1 in non-small cell lung cancer: a review with recommendations
- (2016) Lukas Bubendorf et al. VIRCHOWS ARCHIV
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
- (2016) Eric Polley et al. JNCI-Journal of the National Cancer Institute
- Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer
- (2015) Kosuke Fujino et al. AMERICAN JOURNAL OF PATHOLOGY
- Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis
- (2015) Kyuichi Kadota et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer
- (2015) Theresa A. Boyle et al. Clinical Lung Cancer
- Insm1 controls the differentiation of pulmonary neuroendocrine cells by repressing Hes1
- (2015) Shiqi Jia et al. DEVELOPMENTAL BIOLOGY
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations
- (2015) Lynette M. Sholl et al. Journal of Thoracic Oncology
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
- (2015) Marta Cigognetti et al. MODERN PATHOLOGY
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
- (2015) Yanna Tang et al. Oncotarget
- PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
- (2015) Lars Henning Schmidt et al. PLoS One
- A Review of Preanalytical Factors Affecting Molecular, Protein, and Morphological Analysis of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue: How Well Do You Know Your FFPE Specimen?
- (2014) B. Paige Bass et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
- (2014) Natasha B. Leighl et al. JOURNAL OF CLINICAL ONCOLOGY
- An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators
- (2014) Murry W. Wynes et al. Journal of Thoracic Oncology
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
- (2014) Yoon Jin Cha et al. PLoS One
- Prognostic and predictive biomarkers in lung cancer. A review
- (2014) Erik Thunnissen et al. VIRCHOWS ARCHIV
- NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
- (2014) C. A. French et al. Cancer Discovery
- ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
- (2013) Lynette M. Sholl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas
- (2013) Lénaïg Mescam-Mancini et al. LUNG CANCER
- Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers
- (2013) Akihiko Yoshida et al. MODERN PATHOLOGY
- Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis
- (2012) Di Wu et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- A Study of ΔNp63 Expression in Lung Non-Small Cell Carcinomas
- (2012) Daisuke Nonaka AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum
- (2012) Andrew G. Evans et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma
- (2012) D. E. Bauer et al. CLINICAL CANCER RESEARCH
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent
- (2012) Chris M.J. Conklin et al. Journal of Thoracic Oncology
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
- (2012) Charles M Rudin et al. NATURE GENETICS
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Pathogenesis of NUT Midline Carcinoma
- (2011) Christopher A. French Annual Review of Pathology-Mechanisms of Disease
- NUT midline carcinoma: a neoplasm with diagnostic challenges in cytology
- (2011) B. Zhu et al. CYTOPATHOLOGY
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
- (2011) Natasha Rekhtman et al. MODERN PATHOLOGY
- p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma
- (2011) Justin A Bishop et al. MODERN PATHOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Thyroid Transcription Factor-1 Expression by 2 Monoclonal Antibodies in Pulmonary and Nonpulmonary Primary Tumors
- (2010) Andres Matoso et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody
- (2009) Herbert Haack et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer
- (2009) J. Yu et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started